Nam Q. Bui
YOU?
Author Swipe
View article: Supplementary Fig. 2 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Supplementary Fig. 2 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis Open
Supplementary Fig. 2
View article: Supplementary Fig. 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Supplementary Fig. 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis Open
Supplementary Fig. 1
View article: Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial Open
In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964 ) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), an…
View article: p53 drives lung cancer regression through a TSC2/TFEB-dependent senescence program
p53 drives lung cancer regression through a TSC2/TFEB-dependent senescence program Open
Pharmacological restoration of p53 tumor suppressor function is a conceptually appealing therapeutic strategy for the many deadly cancers with compromised p53 activity, including lung adenocarcinoma (LUAD). However, the p53 pathway has rem…
View article: SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics
SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics Open
View article: Development and implementation of cancer clinical trial patient screening using an electronic medical record-integrated trial matching system
Development and implementation of cancer clinical trial patient screening using an electronic medical record-integrated trial matching system Open
Objectives Clinical trial enrolment is critical for the development and approval of novel cancer therapeutics, but patient identification and recruitment to clinical trials remains low and multiple trials accrue slowly or fail to meet accr…
View article: Musculoskeletal Tumor Care Disparities Prior to Initiation of Treatment Among Newly Diagnosed Adult Patients
Musculoskeletal Tumor Care Disparities Prior to Initiation of Treatment Among Newly Diagnosed Adult Patients Open
Purpose: We investigated care disparities and associated factors along the segments of adult musculoskeletal tumor (MST) care prior to initiation of treatment. Patients and Methods: This cohort included newly diagnosed MST patients who wer…
View article: MultiMed-ST: Large-scale Many-to-many Multilingual Medical Speech Translation
MultiMed-ST: Large-scale Many-to-many Multilingual Medical Speech Translation Open
Multilingual speech translation (ST) and machine translation (MT) in the medical domain enhances patient care by enabling efficient communication across language barriers, alleviating specialized workforce shortages, and facilitating impro…
View article: Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center
Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center Open
Background/Objectives: Locally advanced and metastatic leiomyosarcoma (LMS) is an aggressive cancer with limited treatment options. This single-institution, retrospective study evaluated the efficacy of first-line chemotherapy regimens in …
View article: Data from Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma
Data from Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma Open
Purpose:To characterize factors associated with response to immune checkpoint inhibitors (ICI) in advanced sarcoma.Experimental Design:This is a retrospective study with a cohort of 216 patients with advanced sarcoma treated with ICI betwe…
View article: Supplemental Figure 1 from Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma
Supplemental Figure 1 from Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma Open
Supplemental Figure 1
View article: Supplemental Figure 1 from Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma
Supplemental Figure 1 from Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma Open
Supplemental Figure 1
View article: From the immunotherapy case files
From the immunotherapy case files Open
View article: SCAN-ACT: Adoptive T Cell Therapy Target Discovery Through Single-Cell Transcriptomics
SCAN-ACT: Adoptive T Cell Therapy Target Discovery Through Single-Cell Transcriptomics Open
Summary The FDA approval of T cell receptor-engineered T cells (TCR-T) for synovial sarcoma demonstrates the potential for adoptive T cell therapies (ACTs) in solid tumors. However, the paucity of tumor-specific targets without expression …
View article: Nirogacestat—the pathway to approval of the first treatment for desmoid tumors, a rare disease
Nirogacestat—the pathway to approval of the first treatment for desmoid tumors, a rare disease Open
Drug development for rare diseases can be long, complex, and costly. Desmoid tumors (DT), a rare type of soft-tissue tumor, are associated with substantial and debilitating burden, including disease-specific symptoms (e.g., pain, impaired …
View article: MultiMed-ST: Large-scale Many-to-many Multilingual Medical Speech Translation
MultiMed-ST: Large-scale Many-to-many Multilingual Medical Speech Translation Open
View article: Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers Open
View article: Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study
Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study Open
Purpose: Brain metastases (BM) in sarcomas occur rarely and are associated with poor prognosis. This study is a large retrospective cohort describing the demographic and clinical characteristics of these patients, treatment strategies, and…
View article: 325 CellSARCTx: a single-cell transcriptomics atlas of adoptive cellular therapy targets in soft tissue sarcomas
325 CellSARCTx: a single-cell transcriptomics atlas of adoptive cellular therapy targets in soft tissue sarcomas Open
View article: 8000 Intestinimonas Butyriciproducens As A New Preventive Therapy For Type 2 Diabetes: a Proof Of Concept Randomized Controlled Trial
8000 Intestinimonas Butyriciproducens As A New Preventive Therapy For Type 2 Diabetes: a Proof Of Concept Randomized Controlled Trial Open
Disclosure: V. Antoniotti: None. M. Caputo: None. E. Mollero: None. A. Antonioli: None. S. Tini: None. M. Manfredi: None. S. Gul: None. N. Bui: None. J. Seegers: None. W. De Vos: None. G. Aimaretti: None. F. Prodam: None. Background. The i…
View article: Supplementary Fig. 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Fig. 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Supplementary Fig. 1
View article: Data from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Data from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Purpose: Immune checkpoint inhibition has led to promising responses in soft tissue sarcomas (STSs), but the majority of patients do not respond and biomarkers of response will be crucial. Local ablative therapies may augment systemic resp…
View article: Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Supplementary Tables S1-S5
View article: Supplementary Fig. 2 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Fig. 2 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Supplementary Fig. 2
View article: Supplementary Fig. 2 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Fig. 2 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Supplementary Fig. 2
View article: Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Supplementary Tables S1-S5
View article: Supplementary Fig. 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Fig. 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis Open
Supplementary Fig. 1
View article: Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy Open
View article: 48P Delay of imaging studies in patients with newly diagnosed sarcoma
48P Delay of imaging studies in patients with newly diagnosed sarcoma Open
Delay of diagnosis is common in patients with sarcoma, however, the factors that impact the delay remain incompletely understood. We included patients with newly diagnosed sarcoma who were referred to Stanford sarcoma clinic from August 20…
View article: 14MO Safety of cytoreductive surgery with hyperthermic intraperitoneal gemcitabine and systemic dacarbazine for recurrent uterine leiomyosarcoma: Preliminary results of a phase II trial
14MO Safety of cytoreductive surgery with hyperthermic intraperitoneal gemcitabine and systemic dacarbazine for recurrent uterine leiomyosarcoma: Preliminary results of a phase II trial Open
Uterine leiomyosarcoma (uLMS) is a rare, aggressive gynecologic malignancy affecting 1 in 200,000 women. uLMS frequently recurs within the peritoneal cavity, which may result from tumor rupture or surgical morcellation. Current standard of…